Kunal Jobanputra MD, DM (@knjobanputra) 's Twitter Profile
Kunal Jobanputra MD, DM

@knjobanputra

Community Medical Oncologist || @tatamemorial & KEM Mumbai alumnus | #GUOnc #BreastOnc #ThoracicOnc #SupportiveCare #GlobalOnc

ID: 985857518193823746

linkhttp://drkunaljobanputra.com calendar_today16-04-2018 12:28:43

1,1K Tweet

937 Takipçi

470 Takip Edilen

Dr Amol Akhade (@suyogcancer) 's Twitter Profile Photo

Censoring alert in MATTERHORN (Durva+FLOT vs Placebo+FLOT) 64.8% censored in the durvalumab arm vs 54.0% in placebo ➕ Most were censored as event-free at cut-off, not due to long-term follow-up ⏳ Curves flatten after 24m — but with <20 pts at risk = unstable tails ❗ Median

Censoring alert in MATTERHORN (Durva+FLOT vs Placebo+FLOT)
 64.8% censored in the durvalumab arm vs 54.0% in placebo
➕ Most were censored as event-free at cut-off, not due to long-term follow-up
⏳ Curves flatten after 24m — but with &lt;20 pts at risk = unstable tails
❗ Median
Kunal Jobanputra MD, DM (@knjobanputra) 's Twitter Profile Photo

What is the role of PETCT in postchemotherapy seminoma? by Lucia Nappi 🎯FDG PET highly sensitive 🎯NPV 90-100% even for residual lesions >=3 cm 🎯LOW PPV ~ 23% #ASCO2025

What is the role of PETCT in postchemotherapy seminoma? by <a href="/LuciaNappi4/">Lucia Nappi</a> 
🎯FDG PET highly sensitive
🎯NPV 90-100% even for residual lesions &gt;=3 cm
🎯LOW PPV ~ 23%
#ASCO2025
Kunal Jobanputra MD, DM (@knjobanputra) 's Twitter Profile Photo

Pitfalls during management of mNSGCTs by Dr Lawrence Einhorn Indiana University 🎯 Understand the false positives and minimal persistence of TMs post therapy 🎯No need of CBC on day 8 and day 15 🎯Long-term surveillance for late relapses #ASCO2025 Testicular Cancer UK Testicular Cancer

Pitfalls during management of mNSGCTs by Dr Lawrence Einhorn  <a href="/IndianaUniv/">Indiana University</a>
🎯 Understand the false positives and minimal persistence of TMs post therapy
🎯No need of CBC on day 8 and day 15
🎯Long-term surveillance for late relapses
#ASCO2025 <a href="/TesticularUK/">Testicular Cancer UK</a> <a href="/TestesCancer/">Testicular Cancer</a>
Kunal Jobanputra MD, DM (@knjobanputra) 's Twitter Profile Photo

What do you do when multiple postchenotherapy residual disease in NSGCT? By Lucia Nappi 🎯GET RPLND FIRST 🎯RPLN histology will decide further management 🎯if Fibrosis —> 80% concordance with extra RP lesions, SURVEILLANCE can be considered 🎯Viable or teratoma —> 40%

What do you do when multiple postchenotherapy residual disease in NSGCT?  By <a href="/LuciaNappi4/">Lucia Nappi</a> 

🎯GET RPLND FIRST

🎯RPLN histology will decide further management

🎯if Fibrosis —&gt; 80% concordance with extra RP lesions, SURVEILLANCE can be considered

🎯Viable or teratoma —&gt; 40%
Yüksel Ürün (@dryukselurun) 's Twitter Profile Photo

Because before anything else, every oncologist is a patient advocate. For equity. For access. For every life. 📍#ASCO25 — The place to conquer cancer, together. #CancerCare #Oncology #PatientRights #Advocacy #ConquerCancer @oncoalert ASCO Conquer Cancer, the ASCO Foundation Robin Zon, MD, FACP, FASCO

Because before anything else,
every oncologist is a patient advocate.
For equity. 
For access. 
For every life.
📍#ASCO25 — The place to conquer cancer, together.
#CancerCare #Oncology #PatientRights #Advocacy #ConquerCancer 
@oncoalert <a href="/ASCO/">ASCO</a> <a href="/ConquerCancerFd/">Conquer Cancer, the ASCO Foundation</a> <a href="/ASCOPres/">Robin Zon, MD, FACP, FASCO</a>
Shilpa Gupta (@shilpaonc) 's Twitter Profile Photo

#ASCO25 Was humbled to see a patient approach me on the heels of our presentation yesterday & sharing his experience of achieving CR with EV-P & maintaining it despite on a break from EV for neuropathy. He thanked us for validating his personal experience & providing reassurance

#ASCO25 Was humbled to see a patient approach me on the heels of our presentation yesterday &amp; sharing his experience of achieving CR with EV-P &amp; maintaining it despite on a break from EV for neuropathy. 
He thanked us for validating his personal experience &amp; providing reassurance
Rebecca Shatsky, MD (@dr_rshatsky) 's Twitter Profile Photo

Ok the update to the SOFT and TEXT trial is critically important for the general onc community. Please do not put young women on tamoxifen alone as a default. Ovarian suppression and aromatase inhibitor (not tam) is lifesaving. It’s more important than chemo for many #ASCO25